A small phase II trial that investigated the efficacy of pembrolizumab for EGFR-mutated NSCLC did not demonstrate a response or achieve a sustained duration of treatment for 1 year, even though it was restricted to PD-L1-positive patients, of whom 73% had a PD-L1 expression of ≥50% [107]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.